Zhejiang Huahai Pharmaceutical Co., Ltd. Class A

Zhejiang Huahai Pharmaceutical Co., Ltd. Class A

SSSE:600521
16.61
CNY
+0.09
(+0.54%)
0.61EPS
25.78P/E
24.47BMarket Cap
Apr 27Next Earn

Total Valuation

CNY

As of September 30, 2026, Zhejiang Huahai Pharmaceutical Co., Ltd. Class A carries a market capitalization of 24.47B, placing it among publicly traded companies globally. Its enterprise value stands at 31.01B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap24.47B
Enterprise Value31.01B

Important Dates

Zhejiang Huahai Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for April 27, 2027.

Earnings Date4/27/2027

Share Statistics

As of September 30, 2026, Zhejiang Huahai Pharmaceutical Co., Ltd. Class A has 1.50B shares outstanding.

Shares Outstanding1.50B

Valuation Ratios

As of September 30, 2026, Zhejiang Huahai Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 25.78. The price-to-sales ratio is 2.54, and the price-to-book ratio stands at 2.43.

PE Ratio25.78
PS Ratio2.54
PB Ratio2.43
P/TBV Ratio3.18

Enterprise Valuation

As of September 30, 2026, Zhejiang Huahai Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 27.04 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 27.04 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 31.01B versus a market cap of 24.47B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.23
EV / EBITDA27.04
EV / EBIT27.04

Financial Position

As of September 30, 2026, Zhejiang Huahai Pharmaceutical Co., Ltd. Class A maintains a current ratio of 1.20, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 82.54, indicating elevated leverage, while an interest coverage ratio of 4.77 demonstrates adequate ability to service its debt obligations.

Current Ratio1.20
Quick Ratio0.29
Debt / Equity82.54
Debt / EBITDA7.44
Interest Coverage4.77

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Zhejiang Huahai Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 9.47, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.89 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.32, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.40, useful for judging operating efficiency across full business cycles. The company generates approximately 1.09M in revenue per employee across its workforce of 8,797.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.10 indicates how many times Zhejiang Huahai Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)9.47
Return on Assets (ROA)4.32
Return on Invested Capital (ROIC)4.89
Return on Capital Employed (ROCE)6.40
Revenue Per Employee1.09M
Employee Count8,797.00
Inventory Turnover1.10

Taxes

CNY

Over the twelve months ended September 30, 2026, Zhejiang Huahai Pharmaceutical Co., Ltd. Class A recorded 265.86M in income tax expense. That works out to an effective tax rate of 22.49, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.18B, leaving 945.75M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax265.86M
Effective Tax Rate22.49

Stock Price Statistics

CNY

As of the close on November 17, 2026, Zhejiang Huahai Pharmaceutical Co., Ltd. Class A's stock has declined approximately 10.55% over the past 52 weeks. The 50-day moving average sits at 16.44, while the 200-day moving average is 16.16.

52-Week Price Change-10.55%
50-Day Moving Average16.44
200-Day Moving Average16.16

Income Statement

CNY

Over the twelve months ended September 30, 2026, Zhejiang Huahai Pharmaceutical Co., Ltd. Class A generated 9.60B in revenue and converted that into 945.75M in net income, yielding earnings per share of 0.61. EBITDA reached 1.15B, while operating income came in at 1.49B.

Revenue9.60B
Gross Profit5.64B
Operating Income1.49B
Pretax Income1.18B
Net Income945.75M
EBITDA1.15B
EBIT1.15B
Earnings Per Share (EPS)0.61

Balance Sheet

CNY

As of September 30, 2026, Zhejiang Huahai Pharmaceutical Co., Ltd. Class A holds 2.26B in cash and equivalents against 8.53B in total debt, resulting in a net debt position of 3.75B. Total book value stands at 10.06B, with working capital of 1.57B providing operational flexibility.

Cash & Cash Equivalents2.26B
Total Debt8.53B
Net Debt3.75B
Equity (Book Value)10.06B
Book Value Per Share6.72
Working Capital1.57B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-1.86B

Margins

Over the twelve months ended September 30, 2026, Zhejiang Huahai Pharmaceutical Co., Ltd. Class A posted a gross margin of 58.74, reflecting its pricing power and cost economics. The operating margin of 15.48 and net profit margin of 9.85 provide insight into operational efficiency.

Gross Margin58.74
Operating Margin15.48
Pretax Margin12.31
Profit Margin9.85
EBITDA Margin11.94

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Zhejiang Huahai Pharmaceutical Co., Ltd. Class A paid dividends of 0.22 per share. The dividend payout ratio of 36.89 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -1.81, meaning Zhejiang Huahai Pharmaceutical Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.22
Payout Ratio36.89
Shareholder Yield-1.81

Stock Splits

Zhejiang Huahai Pharmaceutical Co., Ltd. Class A's most recent stock split took place on June 8, 2020 with a 10:11 split ratio.

Last Split Date6/8/2020
Split Ratio10:11

Scores

As of September 30, 2026, Zhejiang Huahai Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 2.47, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.47